Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625. (Q43157127)

14 November 2017

Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625. (English)

1 reference

14 November 2017

1 reference

Michaela Liebig

1

1 reference

14 November 2017

Matthias Gossel

2

1 reference

14 November 2017

Jeremy Pratt

3

1 reference

14 November 2017

Mark Black

4

1 reference

14 November 2017

Guido Haschke

5

1 reference

14 November 2017

Ralf Elvert

6

1 reference

14 November 2017

Hans-Paul Juretschke

7

1 reference

14 November 2017

Claudia Neumann-Haefelin

8

1 reference

14 November 2017

Werner Kramer

9

1 reference

14 November 2017

Andreas W Herling

10

1 reference

14 November 2017

18 February 2010

1 reference

14 November 2017

1 reference

14 November 2017

18

1 reference

14 November 2017

10

1 reference

14 November 2017

1952-1958

1 reference

Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia

14 November 2017

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Obesity as a risk factor for antipsychotic noncompliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Characterization of olanzapine-induced weight gain in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1H-spectroscopic study in Zucker diabetic fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Power matters in closing the phenotyping gap.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

A parametric analysis of olanzapine-induced weight gain in female rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Influence of chronic treatment with olanzapine, clozapine and scopolamine on performance of a learned 8-arm radial maze task in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Olanzapine-associated hypothermia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Olanzapine withdrawal/discontinuation-induced hyperthermia in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

The role of thermogenesis in antipsychotic drug-induced weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Effects of nutritional intervention on body weight and body composition of obese psychiatric patients taking olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Modulation of transmitter release via presynaptic cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Clozapine decreases [3H] CP 55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Energy intake and utilization vary during development in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2010.17

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/OBY.2010.17

1 reference

14 November 2017

1 reference